Parabilis Medicines

United States
Primghar, Iowa, United States, 02140

Company profile

Parabilis Medicines company profile

Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced a novel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.

Business identity

Contact email
[email protected]
Phone number
+1 617-945-9510
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Founded
2016-01-01, Year

Headquarters

Postal code
02140
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
7
Total equity funding
$835.3M
Last funding
Series F / $305M / 2026-01-08
Last equity funding
Series F / $305M
Investors
36
Lead investors
7
Founders
4
Articles
91

Founders and investors

Founders

Greg VerdineJohn McGeeSir David LaneWeiqing Zhou

Lead investors

6 Dimensions CapitalDeerfieldFidelityJanus Henderson InvestorsNextech InvestRA Capital ManagementvenBio Partners

Investors

ARCH Venture PartnersCormorant Asset ManagementGeneral CatalystJanus Henderson InvestorsRA Capital Management